Alyq (Tadalafil) for Pulmonary Hypertension

Overview
Alyq is approved by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH) to improve exercise ability. People eligible for this treatment typically have New York Heart Association (NYHA) Functional Class II - III (2-3) symptoms and etiologies of idiopathic or heritable PAH, or PAH associated with connective tissue diseases. Alyq is also known by its drug name, tadalafil.

Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor. Scientists believe it works by relaxing blood vessels in the lungs, which lowers blood pressure and improves blood flow, thereby enhancing exercise ability in people with PAH.

How do I take it?
Prescribing information states that Alyq should be taken as an oral tablet once daily, with or without food. Use with the medication ritonavir requires dosage adjustments. Alyq should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Alyq include headache.

Rare but serious side effects may include significant hypotension (abnormally low blood pressure), sudden loss of vision (which could indicate nonarteritic ischemic optic neuropathy, or NAION), sudden decrease or loss of hearing, and priapism (prolonged erection lasting more than four hours). Anyone taking this medication should seek emergency treatment if an erection lasts longer than four hours.

For more information about this treatment, visit:

Label: Alyq — Tadalafil Tablet, Film Coated — DailyMed

Alyq — Drugs.com